Studies on Prothrombin Complex Concentrates Contact Factors, Complement Components and Proteinase Inhibitors

Summary

The behaviour of contact factors, complement components and antiproteases during the preparation of prothrombin complex concentrates by adsorption of the clotting components on DEAE-Sephadex has been studied.

The pro-enzymes: factors XII, XI and prekallikrein were removed by pre-elution in function of the salt concentration. In contrast, high molecular weight kininogen was considerably enriched in PCC preparations. C4 of the complement system displayed an analogous behaviour. Cls reached a 4-5 fold plasma concentration but C3 only 30% of the normal plasma level.

The prothrombin complex concentrate contained no antithrombin III nor α₂M nor α2 antiplasmin but a three fold plasma concentration of Cl-inactivator and a 15 fold increase of inter-α- trypsin inhibitor.

NAPTT (Non Activated Partial Thromboplastin Time) ratios did not seem to be in accordance with either the presence or the absence of contact enzymes. Moreover 0.20 M NaCl appeared as the minimal pre-elution molarity necessary to ensure a NAPTT ratio above thrombogenic values.

Molecular alteration of high molecular weight kininogen and C4 was observed and its significance discussed. Complex formation between C1-inactivator and proteases was shown to be another sign of undesirable proteolytic events.

Key words

Prothrombin complex - Contact factors - Complement components - Proteinase inhibitors

• References

• 1 Soulier JP, Blatrix C, Steinbuch M. Fractions “coagulantes” contenant les facteurs de coagulation adsorbables par le phosphate tricalcique. Presse Med 1964; 72: 1223-1228
• 2 Triantaphyllopoulos DC. Intravascular coagulation following injection of prothrombin complex. Am J Clin Pathol 1972; 57: 603-610
• 3 Kasper CK. Post-operative thrombosis in hemophilia B. N Engl J Med 1973; 289: 160
• 4 Steinberg MH, Dreiling BJ. Vascular lesions in hemophilia. N Engl J Med 1973; 289: 592
• 5 Blatt PM, Lundblad RL, Kingdon HS, McLean G, Roberts HR. Thrombogenic materials in prothrombin complex concentrates. Ann Intern Med 1974; 81: 766-770
• 6 Marchesi SI, Barney R. Prothrombin complex concentrates and thrombosis. N Engl J Med 1974; 290: 403-404
• 7 Kasper CK. Thromboembolic complications. Thrombos Diathes Haemorrh 1975; 33: 640-644
• 8 Chandra S, Brummelhuis HG J. Prothrombin complex concentrates for clinical use. Vox Sang 1981; 41: 257-273
• 9 Chandra S, Wickerhauser M. Contact factors are responsible for the thrombogenicity of prothrombin complex. Thromb Res 1979; 14: 189-198
• 10 Hoag MS, Johnson FF, Robinson JA, Aggeler PM. Treatment of hemophilia A with a new clotting factor concentrate. N Engl J Med 1969; 280: 581-586
• 11 Heystek J, Brummelhuis HG I, Krijnen HW. Contributions of the optimal use of human blood. II- The large scale preparation of prothrombin complex, a comparison between the two methods using the anion exchangers DEAE-Cellulose DE-52 and DEAE-Sephadex 1-50. Vox Sang 1973; 25: 113-123
• 12 Suomela H, Mullyla G, Raaska E. Preparation and properties of a therapeutic Factor IX concentrate. Vox Sang 1977; 33: 37-50
• 13 Steinbuch M, Pejaudier L, Tavernier D, Lejars A. A new subfraction of routine fractionation. Blood Transf and Immunohematol 1980; 23: 341-355
• 14 Nemerson Y, Clyne LP. An assay for coagulation factor VII using factor VII-depleted bovine plasma. J Lab Clin Med 1974; 83: 301-303
• 15 Seligsohn U, Osterud B, Rapaport SI. Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VII. Blood 1978; 52: 978-988
• 16 Soulier JP, Gozin D. Assay of Fletcher factor using an artificial clotting reagent and a modified chromogenic assay. Thromb Haemostas 1979; 42: 538-547
• 17 Boffa MC, Dreyer B, Pusineri C. Plasma contact activation and decrease of factor V activity on negatively-charged polyelectrolytes. Thromb Haemostas 1984; 51: 61-64
• 18 Kerbiriou DM, Griffin JH. Human high molecular weight kininogen. Studies of structure-function relationships and of proteolysis of the molecule occurring during contact activation of plasma J Biol Chem 1979; 254: 12020-12027
• 19 Esmon N, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982; 257: 859-864
• 20 Steinbuch M, Kichenin V, Pejaudier L. A simplified technique for the isolation of the fourth complement component. Prep Biochem 1983; 13: 507-518
• 21 Steinbuch M, Granier C, Pejaudier L, Kichenin V. Large scale purification of C1-inactivator (C1-INA), carboxypeptidase N (Cp N) and kallikrein (KK). In: Kinins-III. Fritz N, Back G, Dietze. Haberland GL. (Eds.) Plenum Publishing Corporation; 1983: 193-200
• 22 Kingdon HS, Lundblad RL, Veltkamp JJ, Aronson DL. Potential thrombogenic materials in factor IX concentrates. Thrombos Diathes Haemorrh 1975; 33: 617-631
• 23 Bolutin C, Morris S, Tack B, Prahl J. Purification and structural analysis of the fourth component of human complement. Biochem 1977; 16: 2008-2015
• 24 Pejaudier L, Kichenin V, Audran R, Steinbuch M. Some proteins not belonging to the clotting or to the kallikrein kinin system altered by kallikrein. Hoppe-Seyler’s Z Physiol Chem 1983; 364: 651-654
• 25 Von Zabern I, Bloom EL, Chu V, Gigli I. The fourth component of human complement treated with amines or chaotropes or frozen- thawed (C4b-like C4): interaction with C4 binding protein and cleavage by C3b/C4b inactivator. J Immunol 1982; 128: 1433-1438
• 26 Teisner B, Davey MW, Grudzinskas JG. Interaction between heparin and plasma proteins analysed by crossed immunoelectrophoresis and affinity chromatography. Clin Chim Acta 1983; 127: 413-417
• 27 Kerbiriou DM, Bouma BN, Griffin JH. Immunochemical studies of human high molecular weight kininogen and of its complexes with plasma prekallikrein or kallikrein. J Biol Chem 1980; 255: 3952-3958
• 28 Schapira M, Scott CF, James A, Silver LD, Küppers F, James HL, Colman RW. High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors. Biochem 1982; 21: 567-572
• 29 Gorski JP, Hugli TE, Muller-Eberhart HJ. C4a: the third anaphylatoxin of the human complement system. Proc Nat Acad Sci (Wash) 1979; 76: 5299-5302
• 30 Hugli TE, Kawahara MS, Unson CG, Molinar-Rode R, Erickson BW. The active site of human C4a anaphylatoxin. Mol Immunol 1983; 20: 637-645
• 31 Lijnen HR, Hoylserts M, Collen D. Neutralization of heparin activity by binding to human histidine-rich glycoprotein. Thromb Res 1983; 29: 443-446
• 32 Lämmle B, Eichlisberger R, Marbet GA, Duckert F. Amidolytic activity in normal human plasma assessed with chromogenic substrates. Thromb Res 1979; 16: 245-254